In a nutshell This study investigated the effectiveness of exercise therapy to treat joint pain in patients with breast cancer (BC) treated with aromatase inhibitors (AIs). They found that the overall quality of life was improved after 12 months of exercise therapy in these patients. Some background Breast cancer is the most common cancer...
Read MoreOngoing treatment(s)-Hormonal therapy Posts on Medivizor
What is the optimal timing of exercise therapy for men taking androgen deprivation therapy?
In a nutshell This study aimed to examine the timing of exercise therapy in patients with prostate cancer taking androgen deprivation therapy (ADT). This study found that starting exercise at the onset of ADT helps preserve muscle mass and bone density. Some background Androgen deprivation therapy (ADT) is a treatment option in...
Read MoreLong term results discussing radiotherapy and hormone therapy treatments for patients with prostate cancer
In a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...
Read MoreApalutamide does not affect health-related quality of life in patients with localized prostate cancer
In a nutshell This study investigated the effect of apalutamide (Erleada) on health-related quality of life (H-QoL) in patients with prostate cancer. This study found that apalutimide preserved H-QoL while prolonging time taken for cancer to spread. Some background One treatment option for patients with prostate cancer is androgen...
Read MoreEvaluating optimal duration of androgen deprivation therapy in high risk prostate cancer
In a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients. Some background...
Read MoreComparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer
In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...
Read More10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.
In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...
Read MoreCyroablation for the treatment of early stage prostate cancer
In a nutshell This study evaluated the long-term safety and effectiveness of cryoablation (a process that uses extreme cold to destroy tissue) for patients with early prostate cancer. This study found that cryoablation is safe and effective for early-stage prostate cancer. Some background Cryoablation is a treatment option for early-stage prostate...
Read MoreShould men with castration-resistant metastatic prostate cancer receive further hormone therapy?
In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...
Read MoreFulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer
In a nutshell This study aimed to look at the safety and effectiveness of fulvestrant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor-positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...
Read MoreQuality of life during treatment with chemotherapy and hormonal therapy
In a nutshell This study aimed to compare quality of life between patients with metastatic prostate cancer who were treated with androgen deprivation therapy (ADT) and docetaxel and those who were treated with ADT alone. This study found that ADT and docetaxel was associated with statistically worse QOL at 3 months. However, QOL was better...
Read MoreComparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer
In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...
Read More
